Jingjiao Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jingjiao Zhou has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Jingwei Zhao
Department of Biology and Genetics, The College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, China
4 shared publicationsYi Wang
Department of Biology and Genetics, The College of Life Sciences and Health, Wuhan University of Science and Technology
4 shared publications- Fubing Wang
Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, People’s Republic of China
3 shared publications Juan Huang
Department of Hematology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publications- Jun Zhou
College of Life Sciences and Health, Wuhan University of Science and Technology, No. 2 Huangjiahu West Road, Hongshan District, Wuhan 430081, China
3 shared publications Shenzhen Yuan
Department of Biology and Genetics, The College of Life Sciences and Health, Wuhan University of Science and Technology
3 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1) , 279
Correction to: Computational analysis of multi-omics data reveals CXCL10+ DC-Treg interaction drives immunosuppressive microenvironment in AFP-positive hepatocellular carcinoma
- 14 July 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1) , 279
Open AccessCorrection to: Computational analysis of multi-omics data reveals CXCL10+ DC-Treg interaction drives immunosuppressive microenvironment in AFP-positive hepatocellular carcinoma
- Open Access
- 15 May 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (5) , e1004703
Spatial transcriptomic-metabolic features of tumor foci and tumor capsule in microvascular invasion with hepatocellular carcinoma: A spatial multi-omics study
Background: Microvascular invasion (MVI) is closely related to the recurrence and metastasis of hepatocellular carcinoma (HCC), but the underlying cellular mechanism remains largely elusive. This study aims to elucidate the regional cellular discrepancy between MVI-positive (MVI + ) and MVI-negative (MVI − ) HCC by integrating Spatial transcriptomics (ST) and spatial metabolomics (SM). Methods and findings: ST and SM were performed on six tissue samples from four patients (including 2 MVI + , 2 MVI − , and 2 paratumor tissues), with the integration of 79 public single-cell RNA sequencing datasets of HCC. Patient identity was used as a covariate in the linear equation for regional differentially expressed gene analysis with the ST data. Clinical validation was conducted through multiplex immunofluorescence staining in 79 patients, together with external validation in the cancer genome atlas (TCGA)-liver hepatocellular carcinoma (LIHC) cohort ( n = 299) and an independent microarray dataset ( n = 62). For cell-type-specific metabolic profiling, spatial transcriptomic-metabolic registration was performed. The functional roles of key metabolites were further validated in vitro using inflammatory cancer-associated fibroblasts (iCAFs) derived from hepatic stellate cells (HSCs) and primary CAFs through co-culture models and various functional assays assessing cell proliferation, migration, and invasion. In the tumor lesion, a malignant STMN1 + HMGN2 + GPC3 + cell subtype enriched in MVI + HCC was identified, which exhibited enhanced proliferative activity and was associated with poor prognosis. This finding was further confirmed in a local cohort of 79 patients, where multiplex immunofluorescence staining for the three genes ( STMN1 , HMGN2 , and GPC3 ) showed significantly higher expression in the MVI + group than in the MVI − group ( p = 0.046). Integrated SM analysis further revealed that this cell population underwent metabolic reprogramming characterized by suppressed glycerolipid metabolism. In the tumor capsule, iCAFs-related genes were downregulated in MVI + cases, and iCAFs were located distally from the tumor boundary. Spatial metabolite mapping showed a strong correlation between taurine and iCAFs, and functional assays demonstrated that taurine promotes HCC proliferation and migration by suppressing iCAF activity. One limitation of this study is the small sample size of spatial omics data, which hinders a more complete molecular functional analysis of the STMN1 + HMGN2 + GPC3 + cell subtype and iCAFs in MVI + HCC. Larger-scale ST cohorts are required to further validate and expand the findings of this study. Conclusions: This integrative spatial atlas proposes a hypothesis that there exists a highly proliferative and metabolically reprogrammed malignant cell subtype in the tumor lesion of MVI + HCC, and that taurine in the tumor capsule modulates iCAF activity to influence tumor progression. The exploratory results provide mechanistic insights into MVI-related HCC progression and offer potential avenues for targeted therapeutic intervention of MVI + HCC.
- 15 May 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (5) , e1004703
Open AccessSpatial transcriptomic-metabolic features of tumor foci and tumor capsule in microvascular invasion with hepatocellular carcinoma: A spatial multi-omics study
Background: Microvascular invasion (MVI) is closely related to the recurrence and metastasis of hepatocellular carcinoma (HCC), but the underlying cellular mechanism remains largely elusive. This study aims to elucidate the regional cellular discrepancy between MVI-positive (MVI + ) and MVI-negative (MVI − ) HCC by integrating Spatial transcriptomics (ST) and spatial metabolomics (SM). Methods and findings: ST and SM were performed on six tissue samples from four patients (including 2 MVI + , 2 MVI − , and 2 paratumor tissues), with the integration of 79 public single-cell RNA sequencing datasets of HCC. Patient identity was used as a covariate in the linear equation for regional differentially expressed gene analysis with the ST data. Clinical validation was conducted through multiplex immunofluorescence staining in 79 patients, together with external validation in the cancer genome atlas (TCGA)-liver hepatocellular carcinoma (LIHC) cohort ( n = 299) and an independent microarray dataset ( n = 62). For cell-type-specific metabolic profiling, spatial transcriptomic-metabolic registration was performed. The functional roles of key metabolites were further validated in vitro using inflammatory cancer-associated fibroblasts (iCAFs) derived from hepatic stellate cells (HSCs) and primary CAFs through co-culture models and various functional assays assessing cell proliferation, migration, and invasion. In the tumor lesion, a malignant STMN1 + HMGN2 + GPC3 + cell subtype enriched in MVI + HCC was identified, which exhibited enhanced proliferative activity and was associated with poor prognosis. This finding was further confirmed in a local cohort of 79 patients, where multiplex immunofluorescence staining for the three genes ( STMN1 , HMGN2 , and GPC3 ) showed significantly higher expression in the MVI + group than in the MVI − group ( p = 0.046). Integrated SM analysis further revealed that this cell population underwent metabolic reprogramming characterized by suppressed glycerolipid metabolism. In the tumor capsule, iCAFs-related genes were downregulated in MVI + cases, and iCAFs were located distally from the tumor boundary. Spatial metabolite mapping showed a strong correlation between taurine and iCAFs, and functional assays demonstrated that taurine promotes HCC proliferation and migration by suppressing iCAF activity. One limitation of this study is the small sample size of spatial omics data, which hinders a more complete molecular functional analysis of the STMN1 + HMGN2 + GPC3 + cell subtype and iCAFs in MVI + HCC. Larger-scale ST cohorts are required to further validate and expand the findings of this study. Conclusions: This integrative spatial atlas proposes a hypothesis that there exists a highly proliferative and metabolically reprogrammed malignant cell subtype in the tumor lesion of MVI + HCC, and that taurine in the tumor capsule modulates iCAF activity to influence tumor progression. The exploratory results provide mechanistic insights into MVI-related HCC progression and offer potential avenues for targeted therapeutic intervention of MVI + HCC.
- Open Access
- 19 March 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Computational analysis of multi-omics data reveals CXCL10+ DC-Treg interaction drives immunosuppressive microenvironment in AFP-positive hepatocellular carcinoma
Serum alpha-fetoprotein (AFP) is one of the most widely used clinical diagnostic and prognostic biomarkers for hepatocellular carcinoma (HCC). However, its potential role in guiding treatment strategies remains limited, largely because the tumor microenvironment of AFP-positive HCC has not been well characterized. We integrated multiple types of public transcriptomic data to systematically delineate the features of AFP-positive HCC and their relevance to immunotherapy. Specifically, we used single-cell RNA-seq datasets, bulk RNA-seq data, and spatial transcriptomic data from several independent public cohorts. We found that STMN1+ and AFP+ malignant cell subsets were enriched in AFP-positive tumor tissues, while CYP3A4+ malignant cells were enriched in AFP-negative HCC. Regarding the immune microenvironment, we focused on two key immune cell types: regulatory CD4+ T cells (Tregs) and dendritic cells (DCs). We found that both Tregs and CXCL10+ DCs (DCs with high CXCL10 expression) were elevated in AFP-positive HCC. Moreover, these two cell types showed a highly significant positive correlation across multiple datasets. Spatial transcriptomic analysis revealed their spatial proximity, suggesting that the interaction between CXCL10+ DCs and Tregs shaped the immunosuppressive environment in AFP-positive HCC. Analysis of single-cell and spatial transcriptome data from patients receiving immunotherapy showed that the increased composition and spatial proximity of these two cell types were associated with non-response to immunotherapy. Our study, based on the computation and analysis of public data, revealed that the interaction between CXCL10+ DCs and Tregs may serve as a crucial factor contributing to the formation of the immunosuppressive microenvironment of AFP-positive HCC. This not only enhances researchers' understanding of the AFP-positive HCC microenvironment but also provides a potential immunotherapy target for AFP-positive HCC.
- 19 March 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessComputational analysis of multi-omics data reveals CXCL10+ DC-Treg interaction drives immunosuppressive microenvironment in AFP-positive hepatocellular carcinoma
Serum alpha-fetoprotein (AFP) is one of the most widely used clinical diagnostic and prognostic biomarkers for hepatocellular carcinoma (HCC). However, its potential role in guiding treatment strategies remains limited, largely because the tumor microenvironment of AFP-positive HCC has not been well characterized. We integrated multiple types of public transcriptomic data to systematically delineate the features of AFP-positive HCC and their relevance to immunotherapy. Specifically, we used single-cell RNA-seq datasets, bulk RNA-seq data, and spatial transcriptomic data from several independent public cohorts. We found that STMN1+ and AFP+ malignant cell subsets were enriched in AFP-positive tumor tissues, while CYP3A4+ malignant cells were enriched in AFP-negative HCC. Regarding the immune microenvironment, we focused on two key immune cell types: regulatory CD4+ T cells (Tregs) and dendritic cells (DCs). We found that both Tregs and CXCL10+ DCs (DCs with high CXCL10 expression) were elevated in AFP-positive HCC. Moreover, these two cell types showed a highly significant positive correlation across multiple datasets. Spatial transcriptomic analysis revealed their spatial proximity, suggesting that the interaction between CXCL10+ DCs and Tregs shaped the immunosuppressive environment in AFP-positive HCC. Analysis of single-cell and spatial transcriptome data from patients receiving immunotherapy showed that the increased composition and spatial proximity of these two cell types were associated with non-response to immunotherapy. Our study, based on the computation and analysis of public data, revealed that the interaction between CXCL10+ DCs and Tregs may serve as a crucial factor contributing to the formation of the immunosuppressive microenvironment of AFP-positive HCC. This not only enhances researchers' understanding of the AFP-positive HCC microenvironment but also provides a potential immunotherapy target for AFP-positive HCC.
- Open Access
- 28 February 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
SERPINA4 facilitates colorectal cancer progression through m⁶A-dependent stabilization
Background: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Serine protease inhibitors (SERPINs) have emerged as potential regulators in tumor progression, yet the specific function and regulatory mechanisms of SERPINA4 in CRC remain poorly characterized. Methods: We integrated transcriptomic data from multiple CRC cohorts and conducted survival, pathway, and immune correlation analyses. Functional validation was performed using in vitro proliferation, migration, and invasion assays, as well as in vivo xenograft models. Post-transcriptional regulation of SERPINA4 via m6A modification was examined through MeRIP-qPCR, RNA immunoprecipitation, and decay assays. Results: High expression of SERPINA4 was significantly associated with poor prognosis across multiple survival endpoints. SERPINA4 overexpression promoted CRC cell growth and metastasis in vitro and enhanced tumor formation in vivo. Mechanistically, ALKBH5-mediated m⁶A demethylation reduced SERPINA4 transcript stability by weakening IGF2BP3 association. Rescue experiments with methylation-deficient mutants confirmed the necessity of m6A for SERPINA4-driven oncogenicity. Moreover, SERPINA4 expression correlated with immunosuppressive signatures and reduced CD8 + T cell infiltration. Conclusions: Our findings reveal that SERPINA4 facilitates CRC progression through both tumor-intrinsic mechanisms and modulation of the immune microenvironment. These findings support an epitranscriptomic regulatory mechanism involving an ALKBH5–m6A–IGF2BP3 axis in CRC. SERPINA4 may serve as a prognostic biomarker and therapeutic target in precision oncology.
- 28 February 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessSERPINA4 facilitates colorectal cancer progression through m⁶A-dependent stabilization
Background: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Serine protease inhibitors (SERPINs) have emerged as potential regulators in tumor progression, yet the specific function and regulatory mechanisms of SERPINA4 in CRC remain poorly characterized. Methods: We integrated transcriptomic data from multiple CRC cohorts and conducted survival, pathway, and immune correlation analyses. Functional validation was performed using in vitro proliferation, migration, and invasion assays, as well as in vivo xenograft models. Post-transcriptional regulation of SERPINA4 via m6A modification was examined through MeRIP-qPCR, RNA immunoprecipitation, and decay assays. Results: High expression of SERPINA4 was significantly associated with poor prognosis across multiple survival endpoints. SERPINA4 overexpression promoted CRC cell growth and metastasis in vitro and enhanced tumor formation in vivo. Mechanistically, ALKBH5-mediated m⁶A demethylation reduced SERPINA4 transcript stability by weakening IGF2BP3 association. Rescue experiments with methylation-deficient mutants confirmed the necessity of m6A for SERPINA4-driven oncogenicity. Moreover, SERPINA4 expression correlated with immunosuppressive signatures and reduced CD8 + T cell infiltration. Conclusions: Our findings reveal that SERPINA4 facilitates CRC progression through both tumor-intrinsic mechanisms and modulation of the immune microenvironment. These findings support an epitranscriptomic regulatory mechanism involving an ALKBH5–m6A–IGF2BP3 axis in CRC. SERPINA4 may serve as a prognostic biomarker and therapeutic target in precision oncology.
- Open Access
- 3 February 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (2) , e0227525
Pathogen landscape and synergistic interactions in pediatric ARIs: implications for broad-spectrum surveillance via targeted NGS
Acute respiratory infections (ARIs) in children present complex interactions between respiratory pathogens and host, contributing to high morbidity, hospitalization, and mortality. In this cross-sectional study, 2,044 pediatric in-patient samples were tested for 198 pathogens using targeted next-generation sequencing (tNGS). Pathogen spectrum and co-infection pattern were analyzed alongside blood-test results and clinical data. Pediatric ARIs presented staggered viral epidemics and age-specific infection patterns from 2022 to 2023. Viral infections were predominant in children under 3 years (67.5%). Specific viral-bacterial co-infections were associated with disease severity, including human metapneumovirus (HMPV)- Streptococcus pneumoniae (OR = 3.172, 95% CI: 1.257–8.009), human parainfluenza virus (HPIV)- Fusobacterium nucleatum (3.016, 1.051–8.653), and HPIV- S. pneumoniae (2.825, 1.007–7.927). Subnormal levels of prealbumin and creatinine served as biomarkers for homeostasis disruption in viral-bacterial co-infections. From June to December 2023, Mycoplasma pneumoniae (MP) became the dominant pathogen in preschool (31.3%) and school-age (45.3%) children. High MP loads were correlated with elevated eosinophil, IL-4, and IL-6 and decreased IgG and IL-2, linking to airway hyperreactivity and inflammation. At low MP loads, patients co-detected with human herpesvirus (HHV) (50.0%), or Haemophilus influenzae (40.0%) had a high proportion of severe cases. This study delineated the complex pathogen landscape of pediatric ARIs and highlighted the major role of viral-bacterial and MP-bacterial co-infections. Monitoring these pathogens through tNGS can aid in precise diagnosis and targeted treatment to improve clinical outcomes in children. IMPORTANCE: Moving beyond the outdated “one germ, one disease” model, this study characterizes the etiological and epidemiological landscape and highlights co-infection patterns of virus-bacterium or MP-bacterium in 2044 pediatric respiratory in-patient children across three epidemic phases. Specific pathogen combinations are associated with clinical severity, as well as host immune and metabolic profiles. Our findings underscore the necessity of detecting pathogen-pathogen and host-pathogen dynamics, rather than individual pathogens, thereby informing precision diagnostics and targeted intervention strategies.
- 3 February 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (2) , e0227525
Open AccessPathogen landscape and synergistic interactions in pediatric ARIs: implications for broad-spectrum surveillance via targeted NGS
Acute respiratory infections (ARIs) in children present complex interactions between respiratory pathogens and host, contributing to high morbidity, hospitalization, and mortality. In this cross-sectional study, 2,044 pediatric in-patient samples were tested for 198 pathogens using targeted next-generation sequencing (tNGS). Pathogen spectrum and co-infection pattern were analyzed alongside blood-test results and clinical data. Pediatric ARIs presented staggered viral epidemics and age-specific infection patterns from 2022 to 2023. Viral infections were predominant in children under 3 years (67.5%). Specific viral-bacterial co-infections were associated with disease severity, including human metapneumovirus (HMPV)- Streptococcus pneumoniae (OR = 3.172, 95% CI: 1.257–8.009), human parainfluenza virus (HPIV)- Fusobacterium nucleatum (3.016, 1.051–8.653), and HPIV- S. pneumoniae (2.825, 1.007–7.927). Subnormal levels of prealbumin and creatinine served as biomarkers for homeostasis disruption in viral-bacterial co-infections. From June to December 2023, Mycoplasma pneumoniae (MP) became the dominant pathogen in preschool (31.3%) and school-age (45.3%) children. High MP loads were correlated with elevated eosinophil, IL-4, and IL-6 and decreased IgG and IL-2, linking to airway hyperreactivity and inflammation. At low MP loads, patients co-detected with human herpesvirus (HHV) (50.0%), or Haemophilus influenzae (40.0%) had a high proportion of severe cases. This study delineated the complex pathogen landscape of pediatric ARIs and highlighted the major role of viral-bacterial and MP-bacterial co-infections. Monitoring these pathogens through tNGS can aid in precise diagnosis and targeted treatment to improve clinical outcomes in children. IMPORTANCE: Moving beyond the outdated “one germ, one disease” model, this study characterizes the etiological and epidemiological landscape and highlights co-infection patterns of virus-bacterium or MP-bacterium in 2044 pediatric respiratory in-patient children across three epidemic phases. Specific pathogen combinations are associated with clinical severity, as well as host immune and metabolic profiles. Our findings underscore the necessity of detecting pathogen-pathogen and host-pathogen dynamics, rather than individual pathogens, thereby informing precision diagnostics and targeted intervention strategies.
- Open Access
- 21 May 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-17
Inflammatory metabolite 7α,25-OHC promotes TIMP1 expression in COVID-19 monocytes through synergy effect of SMARCC1/JUND/H3K27ac
Chromatin remodeling factors are involved in the inflammatory responses, contributing to tissue damage and multi-organ dysfunction in COVID-19 patients. However, the underlying mechanisms remain unclear. In this study, high-dimensional analyses of single-cell RNA sequencing and single-cell ATAC sequencing data revealed increased chromatin accessibility at the promoters or enhancers of the pro-inflammatory cytokine tissue inhibitor of metalloproteinase-1 (TIMP1), as well as altered gene transcription profiles in monocytes from COVID-19 patients. Motif enrichment and positive regulators analyses identified SMARCC1, the core subunit of the chromatin remodeling complex, and the transcription factor JUND as positive regulators to co-modulate TIMP1 expression. In-vitro experiments, co-immunoprecipitation and chromatin immunoprecipitation (ChIP)-qPCR, and others, demonstrated the collaboration of SMARCC1 and JUND. Increased 7α,25-dihydroxycholesterol (7α,25-OHC) enhanced SMARCC1-JUND interactions to co-regulate TIMP1 expression. Further investigation indicated that 7α,25-OHC promoted the expression of SMARCC1 and its co-localization with H3K27ac, which involved in the expression of TIMP1 and inflammatory responses. Our study highlights the critical roles of SMARCC1 and JUND in COVID-19 inflammation, and offers the potential targets for the prevention and treatment of COVID-19.
- 21 May 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 82 (1) , 1-17
Open AccessInflammatory metabolite 7α,25-OHC promotes TIMP1 expression in COVID-19 monocytes through synergy effect of SMARCC1/JUND/H3K27ac
Chromatin remodeling factors are involved in the inflammatory responses, contributing to tissue damage and multi-organ dysfunction in COVID-19 patients. However, the underlying mechanisms remain unclear. In this study, high-dimensional analyses of single-cell RNA sequencing and single-cell ATAC sequencing data revealed increased chromatin accessibility at the promoters or enhancers of the pro-inflammatory cytokine tissue inhibitor of metalloproteinase-1 (TIMP1), as well as altered gene transcription profiles in monocytes from COVID-19 patients. Motif enrichment and positive regulators analyses identified SMARCC1, the core subunit of the chromatin remodeling complex, and the transcription factor JUND as positive regulators to co-modulate TIMP1 expression. In-vitro experiments, co-immunoprecipitation and chromatin immunoprecipitation (ChIP)-qPCR, and others, demonstrated the collaboration of SMARCC1 and JUND. Increased 7α,25-dihydroxycholesterol (7α,25-OHC) enhanced SMARCC1-JUND interactions to co-regulate TIMP1 expression. Further investigation indicated that 7α,25-OHC promoted the expression of SMARCC1 and its co-localization with H3K27ac, which involved in the expression of TIMP1 and inflammatory responses. Our study highlights the critical roles of SMARCC1 and JUND in COVID-19 inflammation, and offers the potential targets for the prevention and treatment of COVID-19.
- Open Access
- 14 November 2024
- Published by Taylor & Francis in RNA Biology
- Vol. 21 (1) , 1199-1208
An optimized workflow of full-length transcriptome sequencing for accurate fusion transcript identification
Next-generation sequencing has revolutionized cancer genomics by enabling high-throughput mutation screening yet detecting fusion genes reliably remains challenging. Long-read sequencing offers potential for accurate fusion transcript identification, though challenges persist. In this study, we present an optimized workflow using nanopore sequencing technology to precisely identify fusion transcripts. Our approach encompasses a tailored library preparation protocol, data processing, and fusion gene analysis pipeline. We evaluated the performance using Universal Human Reference RNA and human adenocarcinoma cell lines. Our optimized nanopore sequencing workflow generated high-quality full-length transcriptome data characterized by an extended length distribution and comprehensive transcript coverage. Validation experiments confirmed novel fusion events with potential clinical relevance. Our protocol aims to mitigate biases and enhance accuracy, facilitating increased adoption in clinical diagnostics. Continued advancements in long-read sequencing promise deeper insights into fusion gene biology and improved cancer diagnostics.
- 14 November 2024
- Published by Taylor & Francis in RNA Biology
- Vol. 21 (1) , 1199-1208
Open AccessAn optimized workflow of full-length transcriptome sequencing for accurate fusion transcript identification
Next-generation sequencing has revolutionized cancer genomics by enabling high-throughput mutation screening yet detecting fusion genes reliably remains challenging. Long-read sequencing offers potential for accurate fusion transcript identification, though challenges persist. In this study, we present an optimized workflow using nanopore sequencing technology to precisely identify fusion transcripts. Our approach encompasses a tailored library preparation protocol, data processing, and fusion gene analysis pipeline. We evaluated the performance using Universal Human Reference RNA and human adenocarcinoma cell lines. Our optimized nanopore sequencing workflow generated high-quality full-length transcriptome data characterized by an extended length distribution and comprehensive transcript coverage. Validation experiments confirmed novel fusion events with potential clinical relevance. Our protocol aims to mitigate biases and enhance accuracy, facilitating increased adoption in clinical diagnostics. Continued advancements in long-read sequencing promise deeper insights into fusion gene biology and improved cancer diagnostics.
- Open Access
- 14 October 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-14
FPR1 signaling aberrantly regulates S100A8/A9 production by CD14+FCN1hi macrophages and aggravates pulmonary pathology in severe COVID-19
Excessive alarmins S100A8/A9 escalate the inflammation and even exacerbate immune-driven thrombosis and multi-organ damage. However, the regulatory mechanisms of S100A8/A9 expression in infectious diseases remain unclear. In this study, high-dimensional transcriptomic data analyses revealed a high proportion of CD14+FCN1hi macrophages within the pulmonary niche post-severe SARS-CoV-2 infection. By constructing the S100-coexpression gene list and supervised module scoring, we found that CD14+FCN1hi macrophages presented the highest scores of alarmin S100, and possibly served as the trigger and amplifier of inflammation in severe COVID-19. These CD14+FCN1hi cells lacked the positive regulatory activity of transcription factor PPARγ, and lost their differentiation ability towards mature macrophages. Ex vivo experiments further validated that the epithelial cells with high ORF-3a expression promoted the expression and secretion of S100A8/A9 through ANXA1/SAA1-FPR1 signaling. S100A8/A9 heterodimers, as well as the co-localization of S100A8/A9 with microtubules, were both diminished by the FPR1 inhibitor. Phospho-kinase protein array indicated that STAT3 promoted transcription, and PLC-γ and ERK1/2 pathways were involved in the hetero-dimerization and unconventional secretion of S100A8/A9. Our study highlights the pivotal role of FPR1 signaling in the excessive production of S100A8/A9 and provides a promising target for the prevention and control of severe COVID-19 and post-acute COVID-19 sequelae.
- 14 October 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-14
Open AccessFPR1 signaling aberrantly regulates S100A8/A9 production by CD14+FCN1hi macrophages and aggravates pulmonary pathology in severe COVID-19
Excessive alarmins S100A8/A9 escalate the inflammation and even exacerbate immune-driven thrombosis and multi-organ damage. However, the regulatory mechanisms of S100A8/A9 expression in infectious diseases remain unclear. In this study, high-dimensional transcriptomic data analyses revealed a high proportion of CD14+FCN1hi macrophages within the pulmonary niche post-severe SARS-CoV-2 infection. By constructing the S100-coexpression gene list and supervised module scoring, we found that CD14+FCN1hi macrophages presented the highest scores of alarmin S100, and possibly served as the trigger and amplifier of inflammation in severe COVID-19. These CD14+FCN1hi cells lacked the positive regulatory activity of transcription factor PPARγ, and lost their differentiation ability towards mature macrophages. Ex vivo experiments further validated that the epithelial cells with high ORF-3a expression promoted the expression and secretion of S100A8/A9 through ANXA1/SAA1-FPR1 signaling. S100A8/A9 heterodimers, as well as the co-localization of S100A8/A9 with microtubules, were both diminished by the FPR1 inhibitor. Phospho-kinase protein array indicated that STAT3 promoted transcription, and PLC-γ and ERK1/2 pathways were involved in the hetero-dimerization and unconventional secretion of S100A8/A9. Our study highlights the pivotal role of FPR1 signaling in the excessive production of S100A8/A9 and provides a promising target for the prevention and control of severe COVID-19 and post-acute COVID-19 sequelae.
- Open Access
- 26 January 2024
- Published by Association for Computing Machinery (ACM)
- p. 485-490
Screening and identification of the core genes and drug targets in COVID-19 and coronary artery disease by integrated bioinformatics
The Coronavirus Disease 2019 (COVID-19) is attributed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Studies found that SARS-CoV-2 infection could worsen the coronary artery disease (CAD), and the risk for CAD patients to develop severe COVID-19 would be amplified. However, the potential molecular mechanism between COVID-19 and CAD is not clear yet. By studying transcriptomic data from COVID-19 patients and CAD patients, 106 differentially expressed genes (DEGs) shared in COVID-19 and CAD, which played roles in cardiomyopathy, citric acid cycle (TCA cycle), apoptosis signaling pathways, etc. Protein–protein interaction analyses found that the hub genes, EEF1B2, COX7C, FAU, SNRPD2, TOMM7, HINT1, ATP5ME, ATP5PO, LSM7, and FBL played crucial roles in these two diseases. Transcription factors MYC and CTCF regulated the expression of hub genes. Analyses of Gene regulatory networks and drug-receptor interactions discovered that Ajmaline might be a promising drug. Molecular docking showed that the Ajmaline had strong binding activity to proteins COX7C and HINT1. In this study, the main enriched signaling pathways of these two diseases were studied and COX7C and HINT1 were revealed as potential molecular markers and targets of COVID-19 and CAD, and Ajmaline as a potential drug candidate provided an important theoretical basis for the development of effective therapies for COVID-19 and CAD.
- 26 January 2024
- Published by Association for Computing Machinery (ACM)
- p. 485-490
Open AccessScreening and identification of the core genes and drug targets in COVID-19 and coronary artery disease by integrated bioinformatics
The Coronavirus Disease 2019 (COVID-19) is attributed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Studies found that SARS-CoV-2 infection could worsen the coronary artery disease (CAD), and the risk for CAD patients to develop severe COVID-19 would be amplified. However, the potential molecular mechanism between COVID-19 and CAD is not clear yet. By studying transcriptomic data from COVID-19 patients and CAD patients, 106 differentially expressed genes (DEGs) shared in COVID-19 and CAD, which played roles in cardiomyopathy, citric acid cycle (TCA cycle), apoptosis signaling pathways, etc. Protein–protein interaction analyses found that the hub genes, EEF1B2, COX7C, FAU, SNRPD2, TOMM7, HINT1, ATP5ME, ATP5PO, LSM7, and FBL played crucial roles in these two diseases. Transcription factors MYC and CTCF regulated the expression of hub genes. Analyses of Gene regulatory networks and drug-receptor interactions discovered that Ajmaline might be a promising drug. Molecular docking showed that the Ajmaline had strong binding activity to proteins COX7C and HINT1. In this study, the main enriched signaling pathways of these two diseases were studied and COX7C and HINT1 were revealed as potential molecular markers and targets of COVID-19 and CAD, and Ajmaline as a potential drug candidate provided an important theoretical basis for the development of effective therapies for COVID-19 and CAD.
- Open Access
- 14 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (16) , 12780
Epithelial Galectin-3 Induced the Mitochondrial Complex Inhibition and Cell Cycle Arrest of CD8+ T Cells in Severe/Critical COVID-19
Previous research suggested that the dramatical decrease in CD8+ T cells is a contributing factor in the poor prognosis and disease progression of COVID-19 patients. However, the underlying mechanisms are not fully understood. In this study, we conducted Single-cell RNA sequencing (scRNA-seq) and single-cell T cell receptor sequencing (scTCR-seq) analysis, which revealed a proliferative-exhausted MCM+FASLGlow CD8+ T cell phenotype in severe/critical COVID-19 patients. These CD8+ T cells were characterized by G2/M cell cycle arrest, downregulation of respiratory chain complex genes, and inhibition of mitochondrial biogenesis. CellChat analysis of infected lung epithelial cells and CD8+ T cells found that the galectin signaling pathway played a crucial role in CD8+ T cell reduction and dysfunction. To further elucidate the mechanisms, we established SARS-CoV-2 ORF3a-transfected A549 cells, and co-cultured them with CD8+ T cells for ex vivo experiments. Our results showed that epithelial galectin-3 inhibited the transcription of the mitochondrial respiratory chain complex III/IV genes of CD8+ T cells by suppressing the nuclear translocation of nuclear respiratory factor 1 (NRF1). Further findings showed that the suppression of NRF1 translocation was associated with ERK-related and Akt-related signaling pathways. Importantly, the galectin-3 inhibitor, TD-139, promoted nuclear translocation of NRF1, thus enhancing the expression of the mitochondrial respiratory chain complex III/IV genes and the mitochondrial biogenesis of CD8+ T cells. Our study provided new insights into the immunopathogenesis of COVID-19 and identified potential therapeutic targets for the prevention and treatment of severe/critical COVID-19 patients.
- 14 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (16) , 12780
Open AccessEpithelial Galectin-3 Induced the Mitochondrial Complex Inhibition and Cell Cycle Arrest of CD8+ T Cells in Severe/Critical COVID-19
Previous research suggested that the dramatical decrease in CD8+ T cells is a contributing factor in the poor prognosis and disease progression of COVID-19 patients. However, the underlying mechanisms are not fully understood. In this study, we conducted Single-cell RNA sequencing (scRNA-seq) and single-cell T cell receptor sequencing (scTCR-seq) analysis, which revealed a proliferative-exhausted MCM+FASLGlow CD8+ T cell phenotype in severe/critical COVID-19 patients. These CD8+ T cells were characterized by G2/M cell cycle arrest, downregulation of respiratory chain complex genes, and inhibition of mitochondrial biogenesis. CellChat analysis of infected lung epithelial cells and CD8+ T cells found that the galectin signaling pathway played a crucial role in CD8+ T cell reduction and dysfunction. To further elucidate the mechanisms, we established SARS-CoV-2 ORF3a-transfected A549 cells, and co-cultured them with CD8+ T cells for ex vivo experiments. Our results showed that epithelial galectin-3 inhibited the transcription of the mitochondrial respiratory chain complex III/IV genes of CD8+ T cells by suppressing the nuclear translocation of nuclear respiratory factor 1 (NRF1). Further findings showed that the suppression of NRF1 translocation was associated with ERK-related and Akt-related signaling pathways. Importantly, the galectin-3 inhibitor, TD-139, promoted nuclear translocation of NRF1, thus enhancing the expression of the mitochondrial respiratory chain complex III/IV genes and the mitochondrial biogenesis of CD8+ T cells. Our study provided new insights into the immunopathogenesis of COVID-19 and identified potential therapeutic targets for the prevention and treatment of severe/critical COVID-19 patients.